2. Signaling Pathways
  3. GPCR/G Protein
  4. P2Y Receptor

P2Y Receptor

P2Y Receptor

Related Products

PDF 0.7 MB

P2Y receptors are a class of G protein-coupled receptors (GPCRs) activated by extracellular nucleotides (ATP, UTP, and UDP). There are eight mammalian P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14). The P2Y receptors are expressed in various cell types and play important roles in physiology and pathophysiology including inflammatory responses and neuropathic pain.

The P2Y family can be further divided into a subfamily of five P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11Rs (“P2Y1-like”) that stimulate phospholipase C (PLC) through Gq protein and a second subfamily of P2Y12, P2Y13, and P2Y14Rs (“P2Y12-like”) that inhibit adenylate cyclase through Gi protein. Other effector pathways have been documented, such as coupling of the P2Y11R to Gs as well as to Gq in some cells to induce stimulation of cyclic AMP production.

P2Y Receptor Isoform Specific Products:

P2Y Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-15284S2
    Prasugrel-d4
    Prasugrel-d4 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel-d<sub>4</sub>
  • HY-176143
    P2Y1/P2Y6 antagonist 1
    		Antagonist
    P2Y1/P2Y6 antagonist 1 (Compound 3h) is an indolesulfonylhydrazide derivative. P2Y1/P2Y6 antagonist 1 is an orally active tP2Y1 and rP2Y6 antagonist (IC50 of 9.72 and 1.89 μM, respectively). P2Y1/P2Y6 antagonist 1 can be used in the study of neurological diseases, inflammation, cardiovascular diseases and cancer.
    P2Y1/P2Y6 antagonist 1
  • HY-108654
    PSB 0474
    		Agonist
    PSB 0474 (3-phenacyl-UDP) is a UDP (HY-113359) analog and selective P2Y6 receptor agonist, with an EC50 value of 70 nM for the hP2Y6 receptor. PSB 0474 activates Phospholipase C-coupled receptors to increase intracellular inositol phosphate levels. PSB 0474 enhances NO release by upregulating inducible iNOS and induces Apoptosis. PSB 0474 increases micturition frequency in urine of anesthetized rats, without altering bladder contraction amplitude/duration or causing urothelial damage. PSB 0474 can be used in studies related to chronic brain inflammation.
    PSB 0474
  • HY-RS09916
    P2ry1 Rat Pre-designed siRNA Set A
    		Inhibitor

    P2ry1 Rat Pre-designed siRNA Set A contains three designed siRNAs for P2ry1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    P2ry1 Rat Pre-designed siRNA Set A
  • HY-117356A
    MRS2693 ammonium
    		Agonist
    MRS2693 ammonium is the ammonium dalt form of MRS2693 (HY-117356). MRS2693 ammonium is a selective agonist for P2Y6 with an EC50 of 0.015 μM. MRS2693 ammonium protects C2C12 skeletal muscle cells from TNFα-induced apoptosis. MRS2693 ammonium reduces the activation of NF-kB, activates the ERK1/2 pathway, and has a cytoprotective effect on mouse ischemia-reperfusion injury model[2].
    MRS2693 ammonium
  • HY-W250153A
    Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate
    		Antagonist
    Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.
    Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate
  • HY-137612A
    Sp-UTP-α-S tetrasodium
    		Activator
    Sp-UTP-α-S (Uridine 5-0-1-thiotrirhosphate) tetrasodium is a P2Y2 and P2Y4 receptor activator. Sp-UTP-α-S tetrasodium can be used in cancer research.
    Sp-UTP-α-S tetrasodium
  • HY-15284S
    Prasugrel-d5
    		Inhibitor
    Prasugrel-d5 is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel-d<sub>5</sub>
  • HY-RS09925
    P2RY14 Human Pre-designed siRNA Set A
    		Inhibitor

    P2RY14 Human Pre-designed siRNA Set A contains three designed siRNAs for P2RY14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    P2RY14 Human Pre-designed siRNA Set A
  • HY-B0606A
    Diquafosol
    		Agonist
    Diquafosol (INS365 free base) is a potent P2Y2 agonist. Diquafosol nhibits apoptosis and decreases ROS generation. Diquafosol has the potential for the research of dry eye.
    Diquafosol
  • HY-RS09933
    P2ry4 Rat Pre-designed siRNA Set A
    		Inhibitor

    P2ry4 Rat Pre-designed siRNA Set A contains three designed siRNAs for P2ry4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    P2ry4 Rat Pre-designed siRNA Set A
  • HY-168139
    MRS4865
    		Antagonist
    MRS4865 (compund 7a) is a chimera of a P2Y14 receptor antagonist and a UDP-glucose agonist that protects against neuropathic pain.
    MRS4865
  • HY-172226
    P2Y14R antagonist 3
    		Antagonist
    P2Y14R antagonist 3 (Compound A) is a potent and orally active P2Y14R antagonist with an IC50 value of 23.60 nM and a Kd value of 7.26 μM. P2Y14R antagonist 3 can reduce the degree of lung injury in the Lipopolysaccharides (LPS) (HY-D1056)-induced acute lung injury mice. P2Y14R antagonist 3 can be used for inflammatory diseases.
    P2Y14R antagonist 3
  • HY-103055
    PPTN mesylate
    		Antagonist
    PPTN mesylate is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN mesylate exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity.
    PPTN mesylate
  • HY-107867S1
    (Rac)-Clopidogrel hydrogen-d9 sulfate
    (Rac)-Clopidogrel hydrogen-d9 sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects.
    (Rac)-Clopidogrel hydrogen-d<sub>9</sub> sulfate
  • HY-15876R
    Clopidogrel thiolactone (Standard)
    		Inhibitor
    Cyhalofop (Standard) is the analytical standard of Cyhalofop. This product is intended for research and analytical applications. Cyhalofop (Cyhalofop acid), the primary metabolite of Cyhalofop-butyl (HY-B0861) in susceptible grasses, is the herbicidally active metabolite. Cyhalofop-butyl is an aryloxyphenoxypropionate post-emergence herbicide widely used around the world in agriculture.
    Clopidogrel thiolactone (Standard)
  • HY-173407
    P2Y14R antagonist 4
    		Antagonist
    P2Y14R antagonist 4 (Compound 25l) is an orally active P2Y14R antagonist (IC50: 5.6 nM) with superior binding affinity to P2Y14R over PPTN. P2Y14R antagonist 4 has anti-inflammatory activity and reduces LPS (HY-D1056)-induced proinflammatory cytokines (IL-1β, IL-6, and TNF-α) release.
    P2Y14R antagonist 4
  • HY-117572
    MRS2567
    		Antagonist
    MRS2567 is a P2Y receptor antagonist with the activity of inhibiting contraction of mouse mesenteric arteries. MRS2567 can inhibit the sustained contraction caused by UTP and UDP, and inhibit the Na+, K+, 2Cl- co-transport-dependent signaling pathway, thereby affecting the myogenic tone of mouse mesenteric arteries.
    MRS2567
  • HY-137608A
    Uridine 5'-O-thiodiphosphate trisodium
    		Agonist
    Uridine 5'-O-thiodiphosphate trisodium (UDP-β-S trisodium) is a P2Y6 receptor agonist with an EC50 of 25 nM. Uridine 5'-O-thiodiphosphate trisodium resists degradation by extracellular nucleotidases and stimulates the accumulation of inositol phosphates. Uridine 5'-O-thiodiphosphate trisodium stimulates contractile responses in endothelium-denuded rat mesenteric arteries. As a mitogen, Uridine 5'-O-thiodiphosphate trisodium stimulates DNA synthesis, [3H] thymidine incorporation, protein synthesis, [3H]leucine incorporation, and increases the number of vascular smooth muscle cells. Uridine 5'-O-thiodiphosphate trisodium can be used in the research of cardiovascular diseases such as atherosclerosis.
    Uridine 5'-O-thiodiphosphate trisodium
  • HY-N17826
    YM-254891
    YM-254891 is a YM-254890 (HY-111557) analogue and Gαq/11 inhibitor. YM-254891 can be isolated from the fermentation broth of Chromobacterium sp. QS3666. YM-254891 inhibits ADP-induced platelet aggregation.
    YM-254891
Cat. No. Product Name / Synonyms Application Reactivity
P2Y Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.